Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. M/I Homes, Inc.
18.9% sales growth and 18.93% return on equity
M/I Homes, Inc., together with its subsidiaries, operates as a builder of single-family homes in Ohio, Indiana, Illinois, Michigan, Minnesota, North Carolina, Florida, and Texas, the United States.
M/I Homes, Inc. sales growth this year is anticipated to be 24.1% and 4.1% for next year.
Year-on-year quarterly revenue growth grew by 29.8%, now sitting on 2.88B for the twelve trailing months.
M/I Homes, Inc.'s sales growth for the next quarter is 18.9%. The company's growth estimates for the present quarter and the next is 54.1% and 15.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.93%.
M/I Homes, Inc.'s stock is valued at $44.95 at 18:13 EST, below its 52-week high of $49.44 and way above its 52-week low of $9.62.
M/I Homes, Inc.'s value is higher than its 50-day moving average of $44.82 and way above its 200-day moving average of $40.08.
2. Leidos Holdings, Inc.
12.8% sales growth and 17.6% return on equity
Leidos Holdings, Inc. provides services and solutions in the defense, intelligence, civil, and health markets in the United States and internationally.
Leidos Holdings, Inc. sales growth this year is expected to be 12.1% and 12.2% for next year.
Year-on-year quarterly revenue growth grew by 14.4%, now sitting on 12B for the twelve trailing months.
Leidos Holdings, Inc.'s sales growth for the next quarter is 12.8%. The company's growth estimates for the current quarter and the next is 6% and 23.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.6%.
Leidos Holdings, Inc.'s stock is valued at $102.38 at 18:13 EST, way under its 52-week high of $125.84 and way higher than its 52-week low of $68.00.
Leidos Holdings, Inc.'s value is way higher than its 50-day moving average of $90.45 and way above its 200-day moving average of $92.95.
3. DexCom, Inc.
22.8% sales growth and 20.42% return on equity
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
DexCom, Inc. sales growth this year is anticipated to be 29.4% and 22.2% for next year.
Year-on-year quarterly revenue growth grew by 26.4%, now sitting on 1.82B for the twelve trailing months.
DexCom, Inc.'s sales growth for the next quarter is 22.8%. The company's growth estimates for the ongoing quarter and the next is a negative 20% and 18.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.42%.
DexCom, Inc.'s stock is valued at $312.55 at 18:13 EST, way below its 52-week high of $456.23 and way higher than its 52-week low of $182.07.
DexCom, Inc.'s worth is way under its 50-day moving average of $359.83 and way under its 200-day moving average of $395.12.
4. West Pharmaceutical Services, Inc.
15.6% sales growth and 19.44% return on equity
West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, Ireland, France, Other European countries, and internationally.
West Pharmaceutical Services, Inc. sales growth this year is anticipated to be 14.9% and 11.1% for next year.
Year-on-year quarterly revenue growth grew by 20.1%, now sitting on 2.04B for the twelve trailing months.
West Pharmaceutical Services, Inc.'s sales growth for the next quarter is 15.6%. The company's growth estimates for the ongoing quarter and the next is 36.6% and 18.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.44%.
West Pharmaceutical Services, Inc.'s stock is valued at $266.91 at 18:13 EST, way below its 52-week high of $305.00 and way higher than its 52-week low of $124.53.
West Pharmaceutical Services, Inc.'s value is under its 50-day moving average of $285.78 and above its 200-day moving average of $256.68.
Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Goes Operational: Platform Governance, Local Silicon, and the Physical-AI Data Race
In mid-to-late October 2026, enterprise vendors (Cisco, Fortinet, ServiceNow, Intuit, Salesforce/Braze, Adobe) shipped agent governance, AI security and AI-driven customer engagement products, while a parallel hardware wave (NVIDIA RTX Spark laptops, ASUS, Apple's iPad mini, Microsoft's hybrid local/cloud Windows) pushed AI onto local devices. A third strand, physical AI (Encord, Harvest Praxis, Hesai), argues that real-world sensor data and cheaper edge chips are the next bottleneck. The common thread is the shift from AI experimentation to governed, scaled deployment, with Salesforce's Braze acquisition showing consolidation and fintech players like Intuit tying AI to trusted financial data. The facts support a broad industry theme but contain little direct finance or regulatory evidence, so the AI-finance angle is thin.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
